{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-026588","form_type":"8-K","ticker":"ABT","cik":"0000001800","company_name":"ABBOTT LABORATORIES","filed_at":"2022-10-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.171551+00:00","generated_at":"2026-06-23T02:43:56.498934+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Abbott posts Q3 adj. EPS $1.15, revenue $10.4B; raises full-year EPS guidance","bullets":["Q3 GAAP EPS $0.81, adjusted EPS $1.15; reported sales -4.7%, organic +1.3%.","Raises FY2022 adjusted EPS guidance to $5.17-$5.23; GAAP guidance $3.75-$3.81.","U.S. Medical Devices sales +11.3%; FreeStyle Libre revenues ~$1.0B in Q3.","COVID testing-related sales $1.7B in Q3 vs $1.9B a year ago; full-year outlook $7.8B.","Restarted infant formula production at Sturgis plant; quarterly dividend $0.47/share payable Nov. 15."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-026588","json":"https://secwatch.observer/filing/0001628280-22-026588.json","markdown":"https://secwatch.observer/filing/0001628280-22-026588.md","text":"https://secwatch.observer/filing/0001628280-22-026588.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1800/000162828022026588/0001628280-22-026588-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1800/000162828022026588/abt-20221019.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T02:43:56.498934+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}